PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial

The Lancet

Volumn 376, Issue 9749, 2010, Pages 1329-1337

  McCormack, Sheena ^a   Ramjee, Gita ^b   Kamali, Anatoli ^c   Rees, Helen ^d   Crook, Angela M ^a   Gafos, Mitzy ^e   Jentsch, Ute ^d   Pool, Robert ^f,g   Chisembele, Maureen ^h   Kapiga, Saidi ⁱ   Mutemwa, Richard ^j   Vallely, Andrew ^j,k   Palanee, Thesla ^d   Sookrajh, Yuki ^b   Lacey, Charles J ^l   Darbyshire, Janet ^a   Grosskurth, Heiner ^c   Profy, Albert ^m   Nunn, Andrew ^a   Hayes, Richard ^j   Weber, Jonathan ⁿ   more..

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c MRC/UVRI Uganda Research Unit   (Uganda)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h UNIVERSITY TEACHING HOSPITAL   (Zambia)

ⁱ National Institute for Medical Research   (Tanzania)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k African Medical and Research Foundation Mwanza   (Tanzania)

^l UNIVERSITY OF YORK   (United Kingdom)

^m Endo Pharmaceuticals   (United States)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE; PLACEBO; PRO 2000; AGENTS USED INTRAVAGINALLY; ANTIVIRUS AGENT; NAPHTHALENESULFONIC ACID DERIVATIVE; POLYMER;

ADOLESCENT; ADULT; AFRICA; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; GENITAL SYSTEM DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MENSTRUAL IRREGULARITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREGNANCY; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; ULCER; UNSPECIFIED SIDE EFFECT; AFRICA SOUTH OF THE SAHARA; CONDOM; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; SEXUALLY TRANSMITTED DISEASES; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTIVIRAL AGENTS; CONDOMS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; NAPHTHALENESULFONATES; POLYMERS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 77958104207     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61086-0     Document Type: Article

References (28)

1. UNAIDS/WHO AIDS epidemic update, Joint United Nations Programme on HIV/AIDS (UNAIDS) http://data.unaids.org/pub/Report/2009/JC1700-Epi-Update-2009- en.pdf 2009 (accessed Aug 11, 2010).
2. S Skoler-Karpoff, G Ramjee, K Ahmed Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1977 1987
3. L Van Damme, R Govinden, FM Mirembe Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission N Engl J Med 359 2008 463 472
4. PJ Feldblum, A Adeiga, R Bakare SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria PLoS One 3 2008 e1474
5. V Halpern, F Ogunsola, O Obunge Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria PLoS One 3 2008 e3784
6. Abdool Karim SS, Coletti A, Richardson B, et al. Safety and effectiveness of vaginal microbicides buffer gel and 0.5 PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; Feb 8-11, 2009. (abstr 48LB).
7. Indevus Pharmaceuticals I. Investigator's brochure: universal placebo gel. 2007 (Version 2.0). Lexington: MA, USA.
8. N Bourne, DI Bernstein, J Ireland, AJ Sonderfan, AT Profy, LR Stanberry The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model J Infect Dis 180 1999 203 205 (Pubitemid 29293937)
9. N Cheshenko, MJ Keller, V MasCasullo Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread Antimicrob Agents Chemother 48 2004 2025 2036
10. P Greenhead, P Hayes, PS Watts, KG Laing, GE Griffin, RJ Shattock Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides J Virol 74 2000 5577 5586
11. S Rusconi, M Moonis, DP Merrill Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities Antimicrob Agents Chemother 40 1996 234 236
12. SE Spencer, IE Valentin-Bon, K Whaley, AE Jerse Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model J Infect Dis 189 2004 410 419
13. J Weber, A Nunn, T O'Connor 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo AIDS 15 2001 1563 1568
14. SR Tabet, MM Callahan, CK Mauck Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men J Acquir Immune Defic Syndr 33 2003 476 483
15. KH Mayer, SA Karim, C Kelly Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women AIDS 17 2003 321 329
16. L Van Damme, A Wright, K Depraetere A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women Sex Transm Infect 76 2000 126 130
17. A Kamali, H Byomire, C Muwonge A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda Sex Transm Infect 86 2010 222 226
18. A Nunn, S McCormack, AM Crook, R Pool, C Rutterford, R Hayes Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention Trials 10 2009 99
19. R Pool, CM Montgomery, NS Morar A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme PLoS One 5 2010 e11600
20. R Pool, CM Montgomery, NS Morar Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model PLoS One 5 2010 e11632
21. C Mauck, Z Rosenberg, L Van Damme for the International Working Group on Microbicides Recommendations for the clinical development of topical microbicides: an update AIDS 15 2001 857 868
22. Indevus Pharmaceuticals I. Investigator's Brochure: PRO2000/5 Gel (P). June 16, 2008. Lexington, MA, USA.
23. CM Montgomery, S Lees, J Stadler The role of partnership dynamics in determining the acceptability of condoms and microbicides AIDS Care 20 2008 733 740
24. CJ Lacey, A Wright, JN Weber, AT Profy Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study AIDS 20 2006 1027 1030
25. MJ Keller, B Zerhouni-Layachi, N Cheshenko PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial J Infect Dis 193 2006 27 35
26. MJ Keller, PMM Mesquita, NM Torres Postcoital bioavailability and antiviral activity of 0.5 PRO 2000 gel: implications for future microbicide clinical trials PLoS One 5 2010 e8781
27. L Van Damme, G Ramjee, M Alary Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial Lancet 360 2002 971 977
28. QA Karim, SS Karim, JA Frohlich Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 2010 10.1126/science.1193748 published online July 19.